NovelBeam Technology(SH:688677)2022-04-25 16:00Financial Performance - The company's operating revenue for 2021 was approximately ¥309.67 million, representing a year-on-year increase of 12.53% compared to ¥275.20 million in 2020[21]. - The net profit attributable to shareholders for 2021 was approximately ¥117.73 million, reflecting a year-on-year growth of 22.19% from ¥96.35 million in 2020[21]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 94.006 million, reflecting a growth of 12.02% year-on-year[34]. - The company's total assets increased by 183.19% year-on-year to approximately ¥1.18 billion, compared to ¥417.31 million in 2020[24]. - The basic earnings per share for 2021 was ¥1.41, a decrease of 4.73% from ¥1.48 in 2020[22]. - The company's cash and cash equivalents increased significantly to CNY 723,080,364.17, representing 61.19% of total assets, up from 19.84% in the previous period, reflecting a 773.14% increase[169]. - The company achieved a main business revenue of 30,961.64 million RMB, an increase of 3,511.90 million RMB, representing a year-on-year growth of 12.79%[141]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion in 2021, representing a growth of 20% compared to the previous year[196]. - The company reported a revenue increase of 15% year-over-year, reaching $1.2 billion for the fiscal year 2021[199]. Research and Development - Research and development expenses accounted for 13.35% of operating revenue, an increase of 2.11 percentage points from 11.24% in 2020[22][24]. - The company's R&D investment in 2021 was CNY 41.343 million, an increase of 33.71% from the previous year, accounting for 13.35% of operating revenue[35]. - The total R&D investment amounted to ¥41,342,913.09, representing a 33.71% increase compared to the previous year[113]. - The company has established a clear R&D system with dedicated research organizations focusing on medical imaging technology and intelligent equipment, ensuring coordinated short-term and long-term product planning[41]. - The company has developed several advanced medical imaging systems, including a fluorescence imaging system for surgeries, which has received production licenses and is at the forefront of the industry[118]. - The company is actively researching and developing high-resolution confocal fluorescence endoscopes for early lung cancer detection, with a product registration certificate obtained on January 28, 2022[68]. - The company is focused on integrating optical technology with clinical applications, ensuring rapid response to market demands and technological changes[126]. - The company invested $50 million in R&D for new technologies, focusing on AI and machine learning applications[199]. Market Expansion and Strategy - The company plans to continue expanding its production capacity and investing in research and development to enhance its product offerings[24]. - The company is actively expanding its market presence and has developed partnerships with leading international medical device companies, enhancing its competitive edge[124]. - The company plans to establish final assembly and maintenance lines in the United States to enhance its international operations[135]. - The company aims to accelerate the development of medical endoscope series products, enhancing its existing product line to increase market share[178]. - The company plans to enhance the competitiveness of fluorescence endoscopes by developing 4K fluorescence thoracoscopes and hysteroscopes[180]. - The company is focusing on innovative applications, including 3D endoscope systems, to address clinical challenges and enhance competitive advantage[182]. - The company is exploring partnerships with local firms to enhance distribution channels, aiming to increase sales by 20% in the new regions[196]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share within the next two years[196]. Risk Management and Compliance - The company has not reported any significant risks that could materially affect its operations during the reporting period[4]. - The company has confirmed that there are no non-operating fund occupations by controlling shareholders or related parties[7]. - The company has not violated any decision-making procedures regarding external guarantees[8]. - The company has implemented a comprehensive internal control system to manage risks associated with its expanding business scale[132]. - The company adheres to ISO 13485 and ISO 9001 quality management systems for its medical devices and optical products, ensuring high-quality production standards[49]. Product Development and Innovation - The company completed the R&D and trial production of a 4K fluorescence laparoscope for U.S. clients, with plans for mass production in the second half of 2022[35]. - The company has developed and registered 4K endoscope imaging systems and laparoscopes, establishing a remote network transmission and interaction platform for 4K endoscopic images, enabling real-time surgical guidance for doctors in grassroots hospitals[65]. - The company has developed a new optical structure for endoscopes, achieving 1080P full HD resolution, with distortion below 10% compared to over 20% for conventional endoscopes[72]. - The company has successfully developed a 110° wide-angle arthroscope, surpassing the 70° field of view of mainstream domestic arthroscopes[73]. - The company has developed a depth denoising algorithm that maintains a balance between noise reduction and image detail preservation, achieving an output of 60 frames per second[99]. - The company is developing a 3D fluorescence endoscope technology, which includes dual-light path and single-light path systems, aimed at overcoming the limitations of current 3D endoscopic systems[107]. Corporate Governance - The board of directors and supervisory board members have all attended the board meeting, ensuring accountability for the report's accuracy[5]. - The company has received a standard unqualified audit report from Ernst & Young Huaming[5]. - The company has established a comprehensive quality management system, achieving certifications from major international regulatory bodies, including NMPA, FDA, and CE[128]. Shareholder Information - The total number of shares as of December 31, 2021, is 86,980,000[5]. - The total number of shares held by the chairman, Zheng Anmin, remained unchanged at 10,500,000 shares, with a total pre-tax compensation of 1.85 million CNY[194]. - The total number of shares held by the vice president, Gu Changming, remained unchanged at 120,000 shares, with a total pre-tax compensation of 910,000 CNY[195].